TITLE

The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry

AUTHOR(S)

Michallet, M.; Sobh, M.; Milligan, D.; Morisset, S.; Niederwieser, D.; Koza, V.; Ruutu, T.; Russell, N. H.; Verdonck, L.; Dhedin, N.; Vitek, A.; Boogaerts, M.; Vindelov, L.; Finke, J.; Dubois, V.; van Biezen, A.; Brand, R.; de Witte, T.; Dreger, P.

PUB. DATE

October 2010

SOURCE

Leukemia (08876924);Oct2010, Vol. 24 Issue 10, p1725

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

We analyzed 368 chronic lymphocytic leukemia patients who underwent allogeneic hematopoietic stem cell transplantation reported to the EBMT registry between 1995 and 2007. There were 198 human leukocyte antigen (HLA)-identical siblings; among unrelated transplants, 31 were well matched in high resolution ('well matched' unrelated donor, WMUD), and 139 were mismatched (MM), including 30 matched in low resolution; 266 patients (72%) received reduced-intensity conditioning and 102 (28%) received standard. According to the EBMT risk score, 11% were in scores 1-3, 23% in score 4, 40% in score 5, 22% in score 6 and 4% in score 7. There was no difference in overall survival (OS) at 5 years between HLA-identical siblings (55% (48-64)) and WMUD (59% (41-84)), P=0.82. In contrast, OS was significantly worse for MM (37% (29-48) P=0.005) due to a significant excess of transplant-related mortality. Also OS worsened significantly when EBMT risk score increased. HLA matching had no significant impact on relapse (siblings: 24% (21-27); WMUD: 35% (26-44), P=0.11 and MM: 21% (18-24), P=0.81); alemtuzumab T-cell depletion and stem cell source (peripheral blood) were associated with an increased risk. Our findings support the use of WMUD as equivalent alternative to HLA-matched sibling donors for allogeneic HSCT in CLL, and justify the application of EBMT risk score in this disease.

ACCESSION #

54384166

Tags: HLA histocompatibility antigens;  HEMATOPOIETIC stem cells -- Transplantation;  CHRONIC lymphocytic leukemia -- Patients;  GRAFT versus host disease;  BONE marrow cells;  BLOOD donors;  DISEASES -- Relapse;  T cells

 

Related Articles

• Recent Advances in Bone Marrow Transplantation in Hemoglobinopathies. Michlitsch, Jennifer G.; Walters, Mark C. // Current Molecular Medicine;Nov2008, Vol. 8 Issue 7, p675 

  Allogeneic hematopoietic cell transplantation (HCT) is currently the only treatment with curative potential for sickle cell disease (SCD) and �-thalassemia. HCT was first used to treat SCD and thalassemia more than two decades ago, and with increasing experience this treatment modality has...

• Graft-versus-leukemia Effect of HLA-haploidentical Central-memory T-cells Expanded With Leukemic APCs and Modified With a Suicide Gene. Casucci, Monica; Perna, Serena Kimi; Falcone, Laura; Camisa, Barbara; Magnani, Zulma; Bernardi, Massimo; Crotta, Alessandro; Tresoldi, Cristina; Fleischhauer, Katharina; Ponzoni, Maurilio; Gregori, Silvia; Caligaris Cappio, Federico; Ciceri, Fabio; Bordignon, Claudio; Cignetti, Alessandro; Bondanza, Attilio; Bonini, Chiara // Molecular Therapy;Feb2013, Vol. 21 Issue 2, p466 

  Allogeneic hematopoietic stem cell transplantation (HSCT) from a human leukocyte antigen (HLA)-haploidentical family donor (haplo-HSCT) is a readily available and potentially curative option for high-risk leukemia. In haplo-HSCT, alloreactivity plays a major role in the graft-versus-leukemia...

• HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia. Rutten, C E; van Luxemburg-Heijs, S A P; Griffioen, M; Marijt, E W A; Jedema, I; Heemskerk, M H M; Posthuma, E F M; Willemze, R; Falkenburg, J H F // Leukemia (08876924);Jul2008, Vol. 22 Issue 7, p1387 

  Mismatching for human leukocyte antigen (HLA)-DPB1 in unrelated donor hematopoietic stem cell transplantation (URD-SCT) has been associated with a decreased risk of disease relapse, indicating that HLA-DP may represent a target for graft-versus-leukemia (GVL) reactivity in HLA class...

• Increase of CCR7- CD45RA+ CD8 T cells (TEMRA) in chronic graft-versus-host disease. D'Asaro, M.; Dieli, F.; Caccamo, N.; Musso, M.; Porretto, F.; Salerno, A. // Leukemia (08876924);Mar2006, Vol. 20 Issue 3, p545 

  The article discusses the study regarding the increase of T cells in chronic graft-versus-host disease (cGVHD). A cGVHD still remains as the main factor of long-term outcome and quality of life, among the late effects of hematopoietic stem cell transplantation. Characterized by symptoms similar...

• The management of iron overload in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients: Where do we stand? Sivgin, Serdar; Eser, Bulent // Annals of Hematology;May2013, Vol. 92 Issue 5, p577 

  Iron overload (IO), primarily related to multiple red blood cell transfusions, is a relatively common complication in hematopoietic stem cell transplant (HSCT) recipients. Elevated pretransplant ferritin levels have been reported to increase the risk of non-relapse mortality following HSCT and...

• Genomic studies of GVHD-lessons learned thus far. Ting, C; Alterovitz, G; Merlob, A; Abdi, R // Bone Marrow Transplantation;Jan2013, Vol. 48 Issue 1, p4 

  GVHD remains the most significant complication of hematopoietic SCT, despite advances in HLA matching and the identification of risk various factors. To account for the variation in the incidence and severity of this disease, many genetic association studies have been performed in order to...

• Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation. Svahn, B-M; Remberger, M; Alvin, O; Karlsson, H; Ringdén, O // Bone Marrow Transplantation;May2012, Vol. 47 Issue 5, p706 

  We wanted to evaluate factors associated with high costs after allogeneic haematopoietic SCT (HSCT). We collected all in-patient and outpatient costs during the first year after HSCT over 5 years, from 2003 to 2007. Mean 1-year costs per patient were \[euro]141 493 (95% confidence interval (95%...

• The immunopathology of thymic GVHD. Krenger, Werner; Holl�nder, Georg // Seminars in Immunopathology;2008, Vol. 30 Issue 4, p439 

  The clinical success of allogeneic hematopoietic stem cell transplantation (HSCT) depends on the appropriate reconstitution of the host�s immune system. While recovery of T-cell immunity may occur in transplant recipients via both thymus-dependent and thymus-independent pathways, the...

• G-CSF mobilized vs conventional donor lymphocytes for therapy of relapse or incomplete engraftment after allogeneic hematopoietic transplantation. Abbi, K K S; Zhu, J; Ehmann, W C; Epner, E; Carraher, M; Mierski, J; Talamo, G; Lucas, K; Rybka, W; Claxton, D // Bone Marrow Transplantation;Mar2013, Vol. 48 Issue 3, p357 

  There is little data comparing the activity and toxicity of donor lymphocyte therapy with granulocyte (G)-CSF-mobilized cells (G-donor lymphocyte infusion (DLI)) with the conventionally collected DLI (C-DLI) after allogeneic blood or marrow transplantation. We retrospectively evaluated 67...

Read the Article